ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a report published on Wednesday morning,Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, ALX Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

ALX Oncology Stock Up 9.5 %

ALXO opened at $1.62 on Wednesday. The firm has a market cap of $85.44 million, a P/E ratio of -0.54 and a beta of 1.04. The business’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $3.32. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Insider Activity at ALX Oncology

In related news, Director Rekha Hemrajani bought 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. The trade was a 1,000.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 33.40% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

A number of large investors have recently bought and sold shares of ALXO. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the period. SG Americas Securities LLC boosted its holdings in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in ALX Oncology during the second quarter valued at about $63,000. GSA Capital Partners LLP purchased a new stake in ALX Oncology during the third quarter valued at about $88,000. Finally, Barclays PLC increased its stake in ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after acquiring an additional 42,185 shares during the last quarter. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.